References
- Seltzer M. A., Yap C. S., Silverman D. H., Meta J., Schiepers C., Phelps M. E., et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002; 43: 752–6
- Reubi J. C., Laissue J., Krenning E. P., Lamberts S. W. J. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical applications. J Steroid Biochem Molec Biol 1992; 43: 27–35
- Kwekkeboom D. J., Krenning E. P. Somatostatin receptor imaging. Sem Nucl Med 2002; 32: 84–91
- Virgolini I., Leimer M., Handmaker H., Lastoria S., Bischof C., Muto P., et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998; 58: 1850–9
- Blum J., Handmaker H., Lister-James J., Rinne N., the NeoTect Solitary Pulmonary Nodule Study Group. A multicentre trial with a somatostatin analog 99m-Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000; 117: 1232–8
- Bååth M., Kölbeck K. G., Danielsson R. Somatostatin receptor scintigraphy with 99m-Tc-depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer. A pilot study. Acta Radiol 2004; 45: 833–9
- Shih W. J., Hirschowitz E., Bensadoun E., Woodring J., Ryo Y. U., Kraman S. Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies. Ann Nucl Med 2002; 16: 213–9
- Marten K., Grabbe E. The challenge of the solitary pulmonary nodule. Diagnostic assessment with multislice spiral CT. Clin Imaging 2003; 27: 151–61
- Danielsson R. Bååth M, Svensson L, Forslöw U, Kölbeck KG. Imaging of regional lymph node metastases with 99m-Tc-depreotide in patients with lung cancer. Eur J Nucl Med Mol Imaging 2005; 32: 925–31
- Danielsson R., Bååth M., Kölbeck K. G., Klominek J., Svensson L. Accumulation of 99m-Tc-Depreotide (Neospect) in axillary sweat glands. Clin Nucl Med 2003; 28: 789–90
- Grewal R. K., Dadparvar S., Ju J. Q., Babaria C. J., Cavariaugh T., Sherman M., et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002; 8: 400–4
- Martins T., Lino J. S., Ramos S., Oliveira L. 99m-Tc-depreotide scintigraphy in the evaluation of indeterminate pulmonary lesions: clinical experience. Cancer Biother Radiopharm 2004; 19: 253–9
- Khan D., Menda Y., Kernstine K., Bushnell D., McLaughlin K., Miller S., et al. The utility of 99m-Tc-depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004; 125: 494–501
- Rasmussen K., Madsen H., Rasmussen F., Rasmussen T., Baandrup U., Pilegaard H., et al. The value of HRCT and Tc-depreotide in the evaluation of pulmonary lesions. J Thorac Oncol 2006; 1: 296–301
- Naalsund A., Maublant J. The solitary pulmonary nodule – is it malignant or benign? Diagnostic performance of Tc-depreotide SPECT. Respiration 2006; 73: 634–41
- Thomas L., Balingit A., Morison D., Gilman M. False-positive technetium 99m depreotide scintigraphy resulting from round atelectasis. J Thorac Imaging 2003; 18: 97–9
- Goldsmith S. J., Kostakoglu L. Nuclear medicine imaging of lung cancer. Radiol Clin North Am 2000; 38: 511–24
- Ferran N., Ricart Y., Lopez M., Martinez-Ballarin I., Roca M., Gámez C., et al. Characterization of radiologically indeterminate lung lesions. 99mTc-depreotide SPECT versus 18F-FDG PET. Nucl Med Com 2006; 27: 507–14